These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 32855222)
41. Nutritional Status Improved in Cystic Fibrosis Patients with the G551D Mutation After Treatment with Ivacaftor. Borowitz D; Lubarsky B; Wilschanski M; Munck A; Gelfond D; Bodewes F; Schwarzenberg SJ Dig Dis Sci; 2016 Jan; 61(1):198-207. PubMed ID: 26250833 [TBL] [Abstract][Full Text] [Related]
42. Restoration of R117H CFTR folding and function in human airway cells through combination treatment with VX-809 and VX-770. Gentzsch M; Ren HY; Houck SA; Quinney NL; Cholon DM; Sopha P; Chaudhry IG; Das J; Dokholyan NV; Randell SH; Cyr DM Am J Physiol Lung Cell Mol Physiol; 2016 Sep; 311(3):L550-9. PubMed ID: 27402691 [TBL] [Abstract][Full Text] [Related]
43. Elexacaftor/Ivacaftor/Tezacaftor: First Approval. Hoy SM Drugs; 2019 Dec; 79(18):2001-2007. PubMed ID: 31784874 [TBL] [Abstract][Full Text] [Related]
44. Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation. Trimble AT; Donaldson SH J Cyst Fibros; 2018 Mar; 17(2):e13-e16. PubMed ID: 29079142 [TBL] [Abstract][Full Text] [Related]
45. Ivacaftor in a G551D homozygote with cystic fibrosis. Harrison MJ; Murphy DM; Plant BJ N Engl J Med; 2013 Sep; 369(13):1280-2. PubMed ID: 24066763 [No Abstract] [Full Text] [Related]
46. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm? Jones AM; Barry PJ Thorax; 2015 Jul; 70(7):615-6. PubMed ID: 26071414 [No Abstract] [Full Text] [Related]
47. Celiac Disease in Patients With Cystic Fibrosis on Ivacaftor: A Case Series. Hjelm M; Shaikhkhalil AK J Pediatr Gastroenterol Nutr; 2020 Aug; 71(2):257-260. PubMed ID: 32304549 [TBL] [Abstract][Full Text] [Related]
48. Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections. Hisert KB; Heltshe SL; Pope C; Jorth P; Wu X; Edwards RM; Radey M; Accurso FJ; Wolter DJ; Cooke G; Adam RJ; Carter S; Grogan B; Launspach JL; Donnelly SC; Gallagher CG; Bruce JE; Stoltz DA; Welsh MJ; Hoffman LR; McKone EF; Singh PK Am J Respir Crit Care Med; 2017 Jun; 195(12):1617-1628. PubMed ID: 28222269 [TBL] [Abstract][Full Text] [Related]
49. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. Davies JC; Cunningham S; Harris WT; Lapey A; Regelmann WE; Sawicki GS; Southern KW; Robertson S; Green Y; Cooke J; Rosenfeld M; Lancet Respir Med; 2016 Feb; 4(2):107-15. PubMed ID: 26803277 [TBL] [Abstract][Full Text] [Related]
50. [Real-world effectiveness of ivacaftor in children with cystic fibrosis and the G551D mutation]. Gomez-Pastrana D; Nwokoro C; McLean M; Brown S; Christiansen N; Pao CS An Pediatr (Engl Ed); 2019 Mar; 90(3):148-156. PubMed ID: 30093322 [TBL] [Abstract][Full Text] [Related]
51. Sustained recovery of exocrine pancreatic function in a teenager with cystic fibrosis treated with ivacaftor. Smith H; Rayment JH Pediatr Pulmonol; 2020 Oct; 55(10):2493-2494. PubMed ID: 32678518 [No Abstract] [Full Text] [Related]
52. Ivacaftor potentiation of multiple CFTR channels with gating mutations. Yu H; Burton B; Huang CJ; Worley J; Cao D; Johnson JP; Urrutia A; Joubran J; Seepersaud S; Sussky K; Hoffman BJ; Van Goor F J Cyst Fibros; 2012 May; 11(3):237-45. PubMed ID: 22293084 [TBL] [Abstract][Full Text] [Related]
53. Effect of ivacaftor therapy on exhaled nitric oxide in patients with cystic fibrosis. Grasemann H; Gonska T; Avolio J; Klingel M; Tullis E; Ratjen F J Cyst Fibros; 2015 Nov; 14(6):727-32. PubMed ID: 26168933 [TBL] [Abstract][Full Text] [Related]
54. Efficacy and Safety of CFTR Corrector and Potentiator Combination Therapy in Patients with Cystic Fibrosis for the F508del-CFTR Homozygous Mutation: A Systematic Review and Meta-analysis. Wu HX; Zhu M; Xiong XF; Wei J; Zhuo KQ; Cheng DY Adv Ther; 2019 Feb; 36(2):451-461. PubMed ID: 30554331 [TBL] [Abstract][Full Text] [Related]
55. Positive clinical response to ivacaftor treatment in an individual with the CFTR genotype F508del/V456A. Bratcher PE; Hunt KC; Pickard K; Taylor-Cousar JL J Cyst Fibros; 2019 Mar; 18(2):e9-e10. PubMed ID: 30348612 [No Abstract] [Full Text] [Related]
56. Ivacaftor restores CFTR-dependent sweat gland fluid secretion in cystic fibrosis subjects with S945L alleles. Kim J; Davies Z; Dunn C; Wine JJ; Milla C J Cyst Fibros; 2018 Mar; 17(2):179-185. PubMed ID: 29279204 [TBL] [Abstract][Full Text] [Related]
57. Changes of CFTR functional measurements and clinical improvements in cystic fibrosis patients with non p.Gly551Asp gating mutations treated with ivacaftor. Mesbahi M; Shteinberg M; Wilschanski M; Hatton A; Nguyen-Khoa T; Friedman H; Cohen M; Escabasse V; Le Bourgeois M; Lucidi V; Sermet-Gaudelus I; Bassinet L; Livnat G J Cyst Fibros; 2017 Jan; 16(1):45-48. PubMed ID: 27659740 [TBL] [Abstract][Full Text] [Related]
58. Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction. Brewington JJ; McPhail GL; Clancy JP Expert Rev Respir Med; 2016; 10(1):5-17. PubMed ID: 26581802 [TBL] [Abstract][Full Text] [Related]
59. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator. Ong T; Ramsey BW Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186 [TBL] [Abstract][Full Text] [Related]
60. Ivacaftor for patients with cystic fibrosis. Wainwright CE Expert Rev Respir Med; 2014 Oct; 8(5):533-8. PubMed ID: 25148205 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]